Krystal Biotech (NASDAQ:KRYS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.
According to Zacks, “Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. “
Separately, ValuEngine upgraded Krystal Biotech from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.
Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, May 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.27. equities research analysts predict that Krystal Biotech will post -2.21 earnings per share for the current fiscal year.
In other news, insider Krish S. Krishnan acquired 50,000 shares of the company’s stock in a transaction dated Monday, March 19th. The shares were bought at an average price of $11.00 per share, with a total value of $550,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director R Douglas Norby acquired 9,000 shares of the company’s stock in a transaction dated Wednesday, May 9th. The stock was purchased at an average cost of $10.42 per share, for a total transaction of $93,780.00. The disclosure for this purchase can be found here. 45.80% of the stock is currently owned by insiders.
A hedge fund recently raised its stake in Krystal Biotech stock. Artal Group S.A. lifted its position in Krystal Biotech (NASDAQ:KRYS) by 50.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 150,000 shares of the company’s stock after buying an additional 50,000 shares during the period. Artal Group S.A. owned approximately 1.46% of Krystal Biotech worth $1,578,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 31.40% of the company’s stock.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.